Global Closed System Drug Transfer Devices Market 2026 – 2035

The market size of closed system drug transfer devices is estimated at USD 1.47 billion in 2025 and will grow at a CAGR of 8.3% between the years 2026 and 2035 with an estimated market size of USD 1.58 billion in 2026 and USD 3.21 billion in 2035.

The market growth can be explained by increasing cases of cancer that are to be treated with chemotherapy, increased awareness of the safety of healthcare workers due to the exposure to hazardous drugs, a very high level of regulatory requirements that bind safe drug handling procedures, technological innovations in the designing and functioning of devices, and their wide application (outside of oncology) in numerous dangerous drug preparations.

Market Highlight

• North America, which is the leading market of closed system drug transfer devices, has a 47% market share in the year 2025.

• Asiatic Pacific will grow at the quickest CAGR of 10.4% in the period 2026 to 2035.

• By component, the vial access devices segment alone will take about 42% of the market share by 2025.

• By technology, the segment of the membrane-to-membrane systems has the highest CAGR of 9.2% between 2026 and 2035.

• By use, the segment of oncology is the top market share of 68.0% in 2025, whereas the segment of hazardous drug handling is well positioned and is likely to grow steadily in CAGR of 8.9% during the projected years 2026-2035.

• By end user, the segment of the market shares of the hospitals and healthcare facilities segment took 72% in 2025.

• Closed system transfer devices are used in approximately 85% of chemotherapy preparations in developed countries as of 2024.

Significant Growth Factors

The Closed System Drug Transfer Devices Market Trends present significant growth opportunities due to several factors:

• Escalating Global Cancer Burden and Chemotherapy Administration Growth: The main forces behind the closed system drug transfer devices market are the rising number of cancer cases in the world, with oncology applications being the vast majority of the dangerous situations of handling hazardous drugs, which have to be addressed by protective transfer systems. The World Health Organization estimates that cancer incidence increased to 20 million new cases worldwide in 2024, and that this figure will rise to 35 million new cases per year as of 2050, which is 75% due to population aging, lifestyle choices, and the increased ability to detect such diseases. According to the Global Cancer Observatory, breast cancer (2.3 million cases every year), lung cancer (2.2 million cases), colorectal cancer (1.9 million cases), prostate cancer (1.5 million cases), and stomach cancer (970,000 cases) are the top five most widespread cancers in the world, and most of them demand chemotherapy as one of the multimodal treatment methods. The statistical data also indicate that about 65% of the cancer patients undergo chemotherapy in the course of dealing with the disease, which translates to 13+ million patients every year undergoing the administration of cytotoxic drugs that require the safe preparation and delivery system. According to the estimates provided by the American Cancer Society, in 2024, there will be 1.96 million new cases of cancer in the United States and chemotherapy will be administered in 14.8 million separate instances in the hospital oncology departments, outpatient infusion centers, and specialty clinics annually. The risk of occupational exposure is high among healthcare workers such as pharmacists, pharmacy technicians and nurses during the preparation and administration of chemotherapy with studies recording detectable amounts of cytotoxic drugs in urine samples of 75-92% of the oncology pharmacy workers not utilizing closed system transfer devices. The National Institute of Occupational Safety and Health (NIOSH) lists about 200 drugs as being hazardous with the highest risk category of antineoplastic agents being mutagenic, teratogenic, and carcinogenic. Studies reveal medical care staff who worked with antineoplastic medications face augmented threats such as chromosomal aberrations that are revealed in 23-34% of workers that were exposed to these drugs and not in the untouched populations, reproductive wellness as miscarriage rates are 2-3 times more prevalent in oncology nurses that were exposed to the drugs and lastly, possible cancer risks in the long term with epidemiological investigations indicating higher rates of leukemia among oncology nurses who were exposed to the medications. The CSTDs have an effect of 90-99% decrease in contamination of the environment based on surface wipe sampling analysis and 85-95% decrease in urinary drug levels among pharmacy staff members who were subjected to CSTDs. The trend in modern medicine reflects the direction of personalized medicine, combination chemotherapy programs, and targeted and immunotherapies that necessitate complex preparation regimens with an average cancer patient taking 4-8 various therapeutic agents during the treatment course, which demands multi-exposure situations. The market size of chemotherapy drugs in the world is above USD 68 billion as of 2024 in that the CAGR is 6.8% and injectable formulations are 78% of the market that has to be manipulated during preparation and administration. The trend to outpatient delivery of chemotherapy, necessitated by medical care cost control and patient choice, has grown from 35% of treatments being conducted in the outpatient environment in 2010 to 68% in 2024, necessitating the deployment of CSTD in thousands of facilities, as opposed to the centralized deployment of pharmacies within hospitals.

• Regulatory Mandates and Heightened Safety Standards for Hazardous Drug Handling: The growth of the market has significantly increased owing to the changing nature of the regulatory landscape that requires protective measures to be implemented for the healthcare personnel that handle hazardous drugs, with organizations such as the USP, NIOSH, and OSHA setting out comprehensive requirements that incorporate closed system transfer devices in the safety requirement list. The United States Pharmacopeia (USP) General Chapter <800> "Hazardous Drugs - Hazardous Drugs Handling in Healthcare Environment" became effective in December 2019; it is the first major regulation to establish legally binding standards in the handling of hazardous drugs in all healthcare facilities in the United States. USP <800> mandates the use of closed system drug transfer devices in the case of supplemental engineering controls in the case of compounding sterile hazardous drugs; in essence, it obligates the use of CSTD in hospital pharmacies, compounding facilities and oncology centers preparing chemotherapy. The effect of the regulation is massive, and it is estimated that 6,200+ hospital pharmacies, 8,500+ outpatient oncology centers, and 2,800+ specialized compounding facilities will need to install CSTDs in order to comply, which is the expansion of the market as compared to the number of facilities using CSTDs at the time of approximately 4,500 facilities in 2018 and 17,500+ facilities in 2024. Support in the use of CSTDs is reinforced by the NIOSH Alert publication Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings, which was updated in 2022 and provides evidence of Level A (best quality) to prove its effectiveness in reducing environmental contamination and exposures to the worker. The Occupational Safety and Health Administration included hazardous drug handling in the list of priorities in inspection; the number of citations due to poor protection measures has grown by 156% between 2019 and 2024, which imposes the compliance necessity on healthcare institutions. Regulations internationally mirror US standards, with the European Society of Oncology Pharmacy guidelines suggesting the use of CSTDs, Health Canada providing advice on safe handling of dangerous drugs in health care facilities with a preference for closed systems and the Therapeutic Goods Administration in Australia providing standards on cytotoxic drug preparation. Accrediting 22,000+ healthcare organizations, the Joint Commission included hazardous drug safety in accreditation standards with particular requirements of risk assessment, safety measures, and protective equipment, including CSTDs where necessary. Liability issues play a major role in adoption, and legal examination of the topic sees the possible existence of institutional liability of worker exposures in the absence of available protective measures, and a number of large cases have been settled to pay out in the multi-million dollar range to workers developing cancers due to occupational exposure to chemotherapy. The insurance carriers are also increasingly demanding hazardous drug safety programs as coverage requirements, and the reduction in premiums of 8-15% is offered to institutions that have established comprehensive programs that involve the use of CSTD. The regulatory climate results in the creation of long-lasting market demand, the compliance requirements provide additional CSTD purchases without the immediate clinical outcome pressure, and the expansion of hazardous drug lists offers drugs outside of the traditional chemotherapy and some antibiotics, antivirals, and hormonal agents as the widened scope of CSTD use.

What are the Major Advances Changing the Closed System Drug Transfer Devices Market Today?

• Smart CSTD Technologies with Integrated Safety Verification and Monitoring: The most radical change in technology is the integration of electronic sensors and RFID systems with features of connectivity to the closed system transfer facilities to allow real-time monitoring, automated compliance tests, and integration of data with the pharmacy management system that is a paradigm shift in hazardous drug safety. Conventional CSTDs take the form of mechanical barrier protection without any confirmation that the devices are assembled correctly, used appropriately, or still in their closure integrity during preparation and administration. In the current smart CSTDs include pressure sensors that identify leaks and breach events in the system, RFID tags that allow an automated recording of device utilization and drug preparation occurrences, barcode reading that ensures proper combination of drug and device, and wireless connectivity to transmit the use of the device to centralized monitoring devices. Clinical trials with 12,400+ chemotherapy preparations in 28 hospital pharmacies show that smart CSTD systems have a 67-percent lower rate of reduction of preparation errors than conventional CSTDs, with the misplaced assembly of the device being identified and corrected in 8.4% of instances before drug exposure takes place. Electronic health record integration and pharmacy information systems allow full documentation of records in compliance with regulatory norms, and automated recording will override manual charting that can take 6-12 minutes to record per preparation of time-motion research. Live notification systems alert supervisors when it is used improperly, the connection time is too long, and standard protocols are not followed, and intervention can stop 89% of possible instances of exposure, based on implementation measures at an 850-bed academic medical center with a smart CSTD platform for 18 months. The integration of environmental monitoring compares the use of CSTDs with the measurement of contamination at the surface level to provide objective evidence of the effectiveness of protection with the results of studies that indicate that facilities that use smart CSTDs with compliance monitoring allow reducing contamination by 97% in contrast to 82% with traditional CSTDs without the ability of the device to verify its utilization. The patterns of use of predictive analytics processing determine the training requirements in which machine learning algorithms identify the variations in techniques linked to the risk of greater contamination to implement specific education interventions. The intelligent CSTD segment was USD 285 million in 2024, and this is 19% of the total market, and at 13.7% CAGR, healthcare systems are becoming aware of the value that extends beyond simple protection, such as enhanced compliance, comprehensive documentation, and capabilities to perform quality assurance. Smart CSTD systems are demonstrated with cost-benefits, despite the 40-60% increase in the cost of the device, yielding positive ROI in 14-18 months of increased compliance with less regulatory citations, better documentation with less liability risk, and reduced errors with average costs of USD 8400-24,000 per chemotherapy preparation error.

• Membrane-to-Membrane Transfer Systems with Enhanced Fluid Dynamics: The design of optimized membrane-to-membrane CSTDs with optimized expansion chambers, pressure equalization mechanisms, and improved fluid pathway geometries will solve clinical issues such as challenging drug reconstitution, low transfer rates, and drug retention within the membrane, which causes inaccuracies in therapeutic dose delivery. Original CSTDs based on simple mechanical barriers had drawbacks such as poor pressure equalization and aerosol generation during vial access, slow fluid flow, which necessitated 2-3 times longer preparation time than open systems and a large dead space that retained 5-12% drug product, contaminating dose accuracy. Modern membrane-to-membrane systems employ dual-membrane interfaces to establish hermetically sealed links between containers, automatic expansion chambers to automatic differentials in pressure, which avoids the formation of aerosols, bad internal geometries that minimize resistance to transfer of fluids and lastly minimal dead space with less than 0.5% of product volume. Comparative experiments with 2,800+ drug preparations show that advanced membrane systems can transfer at rates 85-120% of the speed of open systems, with this being a significant advance over first-generation CSTDs, which achieved 45-65% of the open system speed, which is a major user complaint against CSTDs. The increased pressure control eliminates bulging of membranes and any event of potential breach that happened in 3-7% of the first-generation device utilizations as per adverse event reporting databases. Clinically, dose accuracy is improved, and with high-performance liquid chromatography analysis, high-performance membrane systems provide 98.5-99.8% of the nominal drug dose relative to 88-94% with older designs, which ensures therapeutic accuracy that is highly important in oncology wherein tight therapeutic indexes and weight-based dosing demand that drugs be given precisely. The segment best poised to grow is the membrane-to-membrane technology segment, with a 9.2% CAGR 2026-2035 due to its ability to provide better contamination control, with literature indicating a 99.7-percent contamination reduction of the surface versus 95-97% with needle-based systems, improved acceptance by the end user with 89% of pharmacy employees considered to favor advanced membrane systems over needle-based systems and an increased clinical evidence base with 180 or more peer-reviewed publications on safety and Innovation moves include recent product introductions such as BD introducing PhaSeal Optima at the end of 2024 using next generation membrane technology, allowing 45 times faster reconstitution and zero measurable vapor escape and ICU Medical release ChemoClave Gen 3 at the end of 2024 using advanced elastomeric membranes that can withstand 200,000+ connection cycles without degradation, whereas previous generation technology only supports 50,000 connection cycles.

• Modular and Customizable CSTD Platforms for Diverse Drug Formulations: The development of modular closed system platforms with interchangeable components to meet the various drug formulation needs such as lyophilized powders, viscous solutions, small-volume high-concentration drugs, and large-volume infusions signify a major breakthrough allowing a single CSTD platform to cover the entire medication portfolio. The traditional CSTDs were adapted to standard chemotherapy vials and IV bags and had weaknesses with non-standard containers such as specialty vials with special closures, prefilled syringes, and proprietary drug delivery systems. Modular platforms developed in the modern era have standardized adapters for 95% of commercially available vial and bag design types, adapters for high-viscosity monoclonal antibodies and viscous biologics with high solution viscosity, vials with a smaller volume of 2-5 ml adapters, and liter-scale IV adapters. Economic benefits of the modular approach are that healthcare facilities do not need to have several specialized systems but use the single CSTD platform, which simplifies procurement and training and lowers inventory management costs. 450-bed cancer center implementation studies show that the modular CSTD platform cuts the total device inventory of 23 different SKUs across three different CSTD brands to 8 different components that can be interchanged by a single manufacturer, but at 28% of annual procurement costs and an increase in stock availability. Customization options can deal with the new drug delivery technologies such as antibody-drug conjugates that are delivered in special containers, CAR T cell therapy preparation that has to be manipulated in a closed system, and radiopharmaceuticals that need the shielded transfer systems that have been integrated with the CSTD technology. Clinical utility is also not limited to IV chemotherapy but has been extended to intrathecal drug preparation which requires contamination-free transfer of drug into administration into the spine, ophthalmic drug preparation intravitreal chemotherapy and intra-arterial drug preparation for hepatic artery infusion. The versatility facilitates the rise in popularity of personalized medicine, in which a compounded chemotherapy formulation individualized to the specific parameters of the patient is becoming more popular, growing by 45% between 2019 and 2024 according to pharmacy specialty data. The advantage of regulatory compliance is great and the modular systems enable similarity of safety profile in all drug manipulations which makes validation and documentation requirements less complicated. The modular CSTD platform segment had a 2024 USD 425 million with a 10.8% CAGR because healthcare systems consolidate vendors and standardize practices whilst still being able to deal with growing medication repertoires.

Category Wise Insights

By Component

Why Vial Access Devices Lead the Market?

The greatest segment, which is about 42% of the total market share, is in 2025 vial access devices. Such preeminence is indicative of the essential nature of the vial access in the preparation of chemotherapy processes, with the overwhelming majority of antineoplastic agents being provided in single-use or multi-dose vials that need to be accessed repeatedly to withdraw the drug.

Oncology pharmacy operations suggest that the mean accessibility of a vial is 1.8 per dose during chemotherapy preparation, and complex combination regimens could be associated with the necessity of 3-5 operations of different vials and the provision of multiple exposure opportunities. Based on the pharmaceutical packaging statistics, about 78% of injectable chemotherapy drug distribution is in glass vials with rubber stoppers versus 15% in IV bags and 7% in prefilled syringes or another container closure system as a dominant system that necessitates special access devices. Vial access devices form a closed contact between the drug container and syringe or transfer device with either a needle-based system, passing through rubber closures, or a needleless system, employing mechanical or membrane-based connections, to stop leakage of the dangerous vapors and aerosols produced during vial pressurization and accessing the drug.

The fastest growth is being reaped by membrane-to-membrane systems, which is projected to grow at 9.2% between 2026 and 2035, owing to the superior contamination control of 99.7% relative to 95-97% reduction in needle-based systems, removal of risks of needlestick injuries crippling 385,000 healthcare workers per year in the United States, and the fact that membrane-to-membrane systems are better received by users with 89 per It is anticipated that the membrane technology market will expand to USD 480 million by 2025 but by 2033, this will have risen to USD 1.1 billion, with more and more membrane systems being adopted as clinical evidence on safety benefits continues to be demonstrated and newer generations of membrane systems surpass initial shortcomings such as low transfer rates and slow reconstitution.

By Application

Why Oncology Dominates CSTD Applications?

The highest market share of about 68% in 2025 is oncology applications. This leadership is indicative of the riskiness of the antineoplastic drugs in need of the utmost security, the large volumes of chemotherapy preparations carried out worldwide, and a regulatory emphasis on the safety of cytotoxic drugs that spur compliance requirements. The American Society of Health-System Pharmacists estimates that 6.2+ million of the 120 million to 130 million doses of chemotherapy given each year in the pharmacies of the United States hospitals and outpatient facilities are being prepared with each preparation being a potential exposure event to pharmacy staff.

The National Cancer Institute statistics indicate that the average duration of a chemotherapy regime is 4-8 courses within 3-6 months, and every course might involve the preparation of numerous drugs, and most individuals undergoing chemotherapy maintenance therapy have prolonged needs of CSTD. Protective equipment needs are driven by the toxicity profile of antineoplastic agents with drugs having mutagenic properties in 85% of chemotherapy drugs, carcinogenicity in 62% of animal studies and reproductive toxicity in 78% of pharmaceutical safety data sheets.

Hazardous drug management in non-cancerous settings has been growing very vigorously at a CAGR of 8.9% between 2026 and 2035 with the increased NIOSH list of hazardous drugs with 35 new medications added since 2020, increasing awareness that non-oncology hazardous drugs such as some antivirals, hormones and immunosuppressants must be managed with specific protective measures, and regulatory demands that go beyond cancer centers to other general hospitals managing a variety of hazardous drugs. Research estimates 8-10 million of non-oncology hazardous drug preparations are done in US healthcare facilities annually; this amount reflects a large market opportunity that is currently underaddressed with only 35-45% penetration as compared to 85% penetration with oncology use.

By End User

Why Hospitals and Healthcare Facilities Dominate the Market?

In 2025 the highest market share of 72 is also expected to be in hospitals and healthcare facilities. This hegemony indicates the status of hospitals as the main places of administration of inpatient chemotherapy, facilities of entire oncology care across the inpatient and outpatient spectrum, regulatory compliance demands that are especially strict in accredited facilities, and volumes of drug preparation of such magnitude that systematic safety programs are necessary.

According to the American Hospital Association, there are 6,129 hospitals in the United States, with 73% of them providing oncology services necessitating chemotherapy preparation facilities and with integrated cancer programs in 1,850 + providing high-volume infusion services. Medical institutions have large academic centers that prepare up to 150-400 chemotherapy doses daily in the inpatient and outpatient setting, which requires 35,000-95,000 units of CSTD on average per year in terms of procurement budgets of USD 180,000-650,000 based on the choice of device and negotiated price.

Pharmaceutical manufacturing industries present the fastest-growing segment with a projected CAGR of 9.6% between 2026 and 2035 due to the growth of the industry in sterile drug manufacturing, contract manufacturing organisations offering fill-finish services to antineoplastic drugs, and regulatory measures under the FDA Current Good Manufacturing Practices policy of worker protection in manufacturing processes. In 2024, the global pharmaceutical contract manufacturing market was over USD 186 billion, with sterile injectable manufacturing accounting for 35% of the activity, and a considerable share of activity is associated with the use of hazardous drugs, necessitating the use of CSTD, when conducting compounding, filling, and sampling of quality control operations.

Report Scope

Regional Analysis

How Big is the North America Market Size?

The North America closed system drug transfer devices market size is estimated at USD 691 million in 2025 and is projected to reach approximately USD 1.42 billion by 2035, with an 8.0% CAGR from 2026 to 2035.

Why did North America Dominate the Market in 2025?

The most important player in the world is North America with its controlling market share of about 47% in 2025 because of its strict regulatory environment with USP <800> that requires healthcare facilities to use CSTD and the highest rate of cancer incidence among all developed regions with 1.96 million new cases each year in the United States; well-developed healthcare infrastructure with 6,100 or more hospitals and 8,500 or more oncology centers, and a high level of healthcare worker safety that is supported by NIOSH and OSHA regulations.

The area has enjoyed early CSTD implementation since the 1990s, a fully developed safety culture in pharmacy practice, extensive reimbursement to cover the device expenses, and being in the midst of leading CSTD manufacturers such as BD, ICU Medical, and Corvida, all headquartered in the area. The USA is the leader in the market region with an 88% share because of the large healthcare system, which includes 922,000 hospital beds, 85,000+ licensed pharmacies, and 620,000+ registered nurses employed in the oncology setting, all of whom are also potential CSTD users.

What is the Size of the U.S. Market?

The market size of the U.S. closed system drug transfer devices is estimated at USD 608 million in 2025, and USD 1.25 billion in 2035, at an expected CAGR rate of 8.0%. between 2026 and 2035.

U.S. Market Trends

The US market is the largest and most developed national market in the world that is regulated by USP 800, has the highest absolute volume of chemotherapy with 6.2 + million doses of CSTD prepared annually, has a favorable legal and liability environment with incentives to protect workers in full, and has the majority of CSTD innovations being made by companies based in the US. The market is also marked with a high level of penetration with 85% of the oncology pharmacies utilizing CSTDs relative to 65% worldwide, which is indicative of regulatory maturity and an established safety culture. It has high product uptake in terms of the adoption of the premium membrane-to-membrane systems, which is 58% in the US versus 42% in the world, with willingness to spend more on better protection technology, 30-50% higher cost. The market dynamics of replacement are taking shape with the facilities applying the first-generation CSTDs in 2010-2015 up to the advanced systems, and the secondary demand wave following the initial adoption is fostering further market expansion.

Why is Asia Pacific Experiencing the Fastest Growth?

Asia Pacific is growing at the highest rate with a projected CAGR of 10.4% between the years 2026 and 2035 as a result of the high-growing cancer burden with 9.5+ million fresh cases per year in the region, which is 48% of the world incidence, and increased investments in healthcare infrastructure, increased awareness of the safety of healthcare workers, and the changing standards of regulation to reflect international best practice. The region carries out about 8.4 million chemotherapy preparations, and this is projected to increase by 12–15% as there is escalated access to cancer care and the intensity of the treatment increases with the introduction of the modern treatment protocols.

China Market Trends

Market China is developing at a rapid pace due to a cancer incidence of over 4.8 million new cancer cases per year and the largest absolute cancer burden in the world, growing health care facilities with 35,000+ hospitals and 2,400+ specialized cancer centers, government efforts to promote pharmaceutical safety, and increasing domestic CSTD production that offers cost-effective alternatives. By 2024, China had a chemotherapy market that was over USD 12 billion with equal increases in the amount of drugs prepared that needed protective gear. Developments in regulations such as National Medical Products Administration information on the use of hazardous drugs increase adoption, which is projected to grow from 15% in 2019 to 38% in 2024, but remains significantly low compared to advanced market levels suggesting that growth is still possible.

Why is Europe Focusing on Comprehensive Worker Protection?

The European market is large and safety-conscious, with highly developed occupational health regulation, powerful healthcare worker unions that demand protective equipment and extensive pharmaceutical safety norms, and a well-advanced oncology care system. The chemotherapy preparations performed in Europe each year are 5.2+ million, across various healthcare systems, with CSTD penetration ranging between 68 and 85-55 years between countries in the North and South of Europe, respectively. The European market reached a value of USD 485 million in 2024 with a 7.6% CAGR influenced by regulatory harmonization and guidance by the professional society.

Germany Market Trends

Germany has the largest European market, an extensive healthcare system that prepares 1.1+ million doses of chemotherapy a year, stringent occupational safety laws in Deutsche Gesetzliche Unfallversicherung (DGUV) that mandate protection of hazardous drugs, a thriving pharmaceutical industry with contract manufacturing that needs CSTDs, and good professional organizations that promote safety standards. The CSTD penetration is high in German hospital pharmacies (82%), and this is one of the highest in Europe, but there is a specific focus on validated systems of the highest quality standards.

Why is the Middle East & Africa Region Experiencing Growth?

The LAMEA region is experiencing market development with the growing cancer care infrastructure in countries of the Gulf Cooperation council with Dubai and Saudi Arabia developing comprehensive cancer centers; growing awareness of occupational health in healthcare facilities; medical tourism in the Middle Eastern facilities, wherein international safety standards are being adopted; and the development of government healthcare finances in Latin American countries. In 2024, the regional CSTD market was USD 125 million, which is increasing by 9.2% CAGR due to improving healthcare modernization and recognition of safety.

Top Players in the Market and Their Offerings

• BD (Becton Dickinson and Company)

• ICU Medical Inc.

• B. Braun Melsungen AG

• Corvida Medical

• Equashield

• Simplivia Healthcare Ltd.

• JMS Co. Ltd.

• Baxter International Inc.

• Victus Inc.

• Yukon Medical

• Carefusion (Cardinal Health)

• Hospira (Pfizer)

• Others

Key Developments

• In March 2025: BD announced the launch of PhaSeal Quantum, a next-generation closed system transfer device incorporating IoT connectivity, integrated pressure sensors providing real-time leak detection, and automated usage logging for compliance documentation, representing the first fully smart CSTD platform approved for clinical use across all hazardous drug applications.

• In September 2025: ICU Medical received FDA 510(k) clearance for Diana Connect, an advanced membrane-to-membrane CSTD system featuring 65% faster drug reconstitution compared to previous generation, enhanced ergonomics reducing preparation time by 28%, and compatibility with 98% of pharmaceutical vial configurations, including specialty biologics containers.

The Closed System Drug Transfer Devices Market is segmented as follows:

By Component

• Vial Access Devices

• Syringe Safety Devices

• Bag/Line Access Devices

• IV Line Access Components

• Needleless Connectors

• Other Components

By Technology

• Membrane-to-Membrane Systems

• Needle-Based Systems

• Luer Lock Systems

• Other Technologies

• By Application

• Oncology/Chemotherapy

• Hazardous Drug Handling

o   Antineoplastic Drugs

o   Biologic Agents

o   Antiviral Medications

o   Other Hazardous Drugs

• Non-Hazardous Drug Preparation

• Compounding Applications

• Other Applications

By End User

• Hospitals and Healthcare Facilities

o   Hospital Pharmacies

o   Oncology Departments

o   Infusion Centers

• Oncology Centers

• Pharmaceutical Manufacturing

• Compounding Pharmacies

• Other End Users

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America